CXCL9 chemokine in ulcerative colitis

被引:30
作者
Elia, G. [1 ]
Guglielmi, G. [2 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Via Savi 10, I-56126 Pisa, Italy
[2] Univ Hosp Pisa, Operat Unit Prevent & Occupat Med, Pisa, Italy
来源
CLINICA TERAPEUTICA | 2018年 / 169卷 / 05期
关键词
CXCR3; CXCL9; ulcerative colitis;
D O I
10.7417/CT.2018.2085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this narrative review is to highlight the role of CXCL9 in Ulcerative Colitis (UC), in order to understand the mechanism underlying the inflammation in UC and to investigate also if Th1- chemokines could be useful as a marker of disease. It was shown that chemokine (C-X-C motif) receptor (CXCR)3 and its ligand chemokine, monokine induced by interferon (IFN)-gamma(MIG)/chemokine (C-X-C motif) ligand 9 (CXCL)9, are highly overexpressed both in the intestinal mucosa of mice with experimental colitis and in patients with UC (specifically, in lymphocytes, macrophages and epithelial cells). In epithelial colonic cells CXCL9 expression is increased by IFN-gamma. MIG has an important role in the recruitment of mononuclear cells and granulocytes, so in maintaining the inflammation in UC. Since serum CXCL9 levels are related with UC disease activity, it could be a marker for the responsiveness of patients to treatments. It has been recently suggested that blocking CXCL9 may be a potentially effective therapy for moderately-to-severely active UC.
引用
收藏
页码:E235 / E241
页数:7
相关论文
共 118 条
[1]   Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study [J].
Antonelli, A. ;
Fallahi, P. ;
Ferrari, S. M. ;
Pupilli, C. ;
d'Annunzio, G. ;
Lorini, R. ;
Vanelli, M. ;
Ferrannini, E. .
DIABETIC MEDICINE, 2008, 25 (11) :1349-1353
[2]   Serum levels of the interferon-γ-inducible a chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy [J].
Antonelli, A. ;
Fallahi, P. ;
Rotondi, M. ;
Ferrari, S. M. ;
Serio, M. ;
Miccoli, P. .
BRITISH JOURNAL OF SURGERY, 2006, 93 (10) :1226-1231
[3]   Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy [J].
Antonelli, A ;
Rotondi, M ;
Fallahi, P ;
Romagnani, P ;
Ferrari, SM ;
Barani, L ;
Ferrannini, E ;
Serio, M .
CLINICAL ENDOCRINOLOGY, 2006, 64 (02) :189-195
[4]  
Antonelli A, 2011, J BIOL REG HOMEOS AG, V25, P655
[5]  
Antonelli A, 2002, CLIN EXP RHEUMATOL, V20, P693
[6]   Autoimmunity to CD38 and GAD in Type I and Type II diabetes:: CD38 and HLA genotypes and clinical phenotypes [J].
Antonelli, A ;
Tuomi, T ;
Nannipieri, M ;
Fallahi, P ;
Nesti, C ;
Okamoto, H ;
Groop, L ;
Ferrannini, E .
DIABETOLOGIA, 2002, 45 (09) :1298-1306
[7]  
Antonelli A, 2009, CLIN EXP RHEUMATOL, V27, P22
[8]   Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease [J].
Antonelli, A ;
Fallahi, P ;
Nesti, C ;
Pupilli, C ;
Marchetti, P ;
Takasawa, S ;
Okamoto, H ;
Ferrannini, E .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 126 (03) :426-431
[9]   Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets [J].
Antonelli, A ;
Baj, G ;
Marchetti, P ;
Fallahi, P ;
Surico, N ;
Pupilli, C ;
Malavasi, F ;
Ferrannini, E .
DIABETES, 2001, 50 (05) :985-991
[10]   PRETIBIAL MYXEDEMA AND HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN TREATMENT [J].
ANTONELLI, A ;
NAVARRANNE, A ;
PALLA, R ;
ALBERTI, B ;
SARACINO, A ;
MESTRE, C ;
ROGER, P ;
AGOSTINI, S ;
BASCHIERI, L .
THYROID, 1994, 4 (04) :399-408